BioNTech SE (BNTX) Payables (2018 - 2025)
BioNTech SE (BNTX) posted Payables of $622.6 million for Q4 2025, up 33.22% sequentially from $467.4 million in Q3 2025, and up 36.55% YoY from $456.0 million in Q4 2024.
BioNTech SE (BNTX) Payables (2018 - 2025) Analysis & Trends
BioNTech SE has reported Payables for 8 years, with the latest figure at $622.6 million in Q4 2025.
- Quarterly Payables rose 36.55% year-over-year to $622.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $622.6 million (up 36.55% YoY) and the FY2025 annual result came in at $604.3 million, up 32.54% from the prior year.
- Payables grew to $622.6 million in Q4 2025 per BNTX's latest filing, from $467.4 million in the prior quarter.
- Over five years, Payables peaked at $949.3 million in Q2 2024 and troughed at $34.3 million in Q1 2023.
- A 5-year average of $439.3 million and a median of $434.7 million in 2021 frame the typical range for Payables.
- The sharpest annual moves came in 2021 and 2023: Payables soared 1829.06% in 2021, then sank 89.04% in 2023.
- Over 5 years, Payables stood at $527.9 million in 2021, then sank by 60.15% to $210.4 million in 2022, then surged by 82.23% to $383.4 million in 2023, then rose by 18.94% to $456.0 million in 2024, then soared by 36.55% to $622.6 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $622.6 million, $467.4 million, and $570.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 622.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 622.65 Mn |
| Sep 30, 2025 | 467.39 Mn |
| Jun 30, 2025 | 570.73 Mn |
| Mar 31, 2025 | 466.83 Mn |
| Dec 31, 2024 | 455.97 Mn |
| Sep 30, 2024 | 837.50 Mn |
| Jun 30, 2024 | 949.28 Mn |
| Mar 31, 2024 | 324.60 Mn |
| Dec 31, 2023 | 383.36 Mn |
| Sep 30, 2023 | 242.43 Mn |
| Jun 30, 2023 | 248.93 Mn |
| Mar 31, 2023 | 34.35 Mn |
| Dec 31, 2022 | 210.38 Mn |
| Sep 30, 2022 | 537.91 Mn |
| Jun 30, 2022 | 531.07 Mn |
| Mar 31, 2022 | 313.24 Mn |
| Dec 31, 2021 | 527.94 Mn |
| Sep 30, 2021 | 338.10 Mn |
| Jun 30, 2021 | 309.26 Mn |
| Mar 31, 2021 | 413.50 Mn |